Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013.
Remes K, Anttila P, Silvennoinen R, Putkonen M, Ollikainen H, Terävä V, Sinisalo M, Kananen K, Schain F, Castren-Kortegangas P, Järvinen TM, Pisini M, Wahl F, Dixon T, Leval A. Remes K, et al. Among authors: pisini m. PLoS One. 2018 Dec 5;13(12):e0208507. doi: 10.1371/journal.pone.0208507. eCollection 2018. PLoS One. 2018. PMID: 30517181 Free PMC article.
Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape.
Borgsten F, Gatopoulou X, Pisini M, Tambour M, Schain F, Jones CV, Kwok KHM, Batyrbekova N, Björkholm M. Borgsten F, et al. Among authors: pisini m. Eur J Haematol. 2021 Jul;107(1):92-103. doi: 10.1111/ejh.13623. Epub 2021 May 5. Eur J Haematol. 2021. PMID: 33728732
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT).
Dimopoulos MA, Cavo M, Mateos MV, Facon T, Heeg B, van Beekhuizen S, Gebregergish SB, Nair S, Pisini M, Lam A, Slavcev M. Dimopoulos MA, et al. Among authors: pisini m. Leuk Lymphoma. 2020 Mar;61(3):714-720. doi: 10.1080/10428194.2019.1682571. Epub 2019 Nov 5. Leuk Lymphoma. 2020. PMID: 31686559
Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjusted indirect comparison methodology.
Van Sanden S, Pisini M, Duchesne I, Mehnert A, Belsey J. Van Sanden S, et al. Among authors: pisini m. Curr Med Res Opin. 2016;32(1):147-54. doi: 10.1185/03007995.2015.1106934. Epub 2015 Oct 29. Curr Med Res Opin. 2016. PMID: 26455472
Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service.
Westerhout KY, Bouwmeester W, Duchesne I, Pisini M, Piena MA, Damele F, Gueron B, Treur M, Belsey J. Westerhout KY, et al. Among authors: pisini m. Clinicoecon Outcomes Res. 2017 Feb 27;9:163-172. doi: 10.2147/CEOR.S117650. eCollection 2017. Clinicoecon Outcomes Res. 2017. PMID: 28280374 Free PMC article.